MACROGENICS, INC. Stock-Based Compensation
MACROGENICS, INC. (MGNX) reported Stock-Based Compensation of $4.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- MACROGENICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.97M, a 46.50% decline year-over-year.
- MACROGENICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.65M, a 39.67% decline year-over-year.
- MACROGENICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.66M, a 76.38% decline year-over-year.
- MACROGENICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.55M, a 40.55% decline year-over-year.
- MACROGENICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $14.29M, a 51.47% decline from fiscal 2024.
- MACROGENICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $29.44M, a 60.23% increase from fiscal 2023.
- MACROGENICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $18.37M, a 10.10% decline from fiscal 2022.
- MACROGENICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $20.44M, a 11.62% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $4.62M 10-Q · filed 2026-08-14 | $7.28M derived: sum of 3 quarters · filed 2026-08-14 | $10.83M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $2.65M 10-Q · filed 2026-05-13 | $5.31M derived: sum of 2 quarters · filed 2026-05-13 | $8.86M derived: sum of 3 quarters · filed 2026-05-13 | $12.55M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $6.21M derived: sum of 2 quarters · filed 2026-03-09 | $9.90M derived: sum of 3 quarters · filed 2026-08-14 | $14.29M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $3.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $7.24M derived: sum of 2 quarters · filed 2026-08-14 | $11.63M 10-Q · filed 2025-11-12 | $22.89M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $3.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $8.08M 10-Q · filed 2026-08-14 | $19.34M derived: sum of 3 quarters · filed 2026-08-14 | $25.31M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $4.39M 10-Q · filed 2026-05-13 | $15.65M derived: sum of 2 quarters · filed 2026-05-13 | $21.62M derived: sum of 3 quarters · filed 2026-05-13 | $28.27M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $11.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $17.23M derived: sum of 2 quarters · filed 2026-03-09 | $23.89M derived: sum of 3 quarters · filed 2026-03-09 | $29.44M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $5.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $12.62M derived: sum of 2 quarters · filed 2025-11-12 | $18.17M 10-Q · filed 2025-11-12 | $22.53M derived: sum of 4 quarters · filed 2026-03-09 | |||
| 2024-06-30 | $6.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $12.20M 10-Q · filed 2025-08-14 | $16.56M derived: sum of 3 quarters · filed 2026-03-09 | $21.35M derived: sum of 4 quarters · filed 2026-03-09 | |||
| 2024-03-31 | $5.55M 10-Q · filed 2025-05-13 | $9.91M derived: sum of 2 quarters · filed 2026-03-09 | $14.70M derived: sum of 3 quarters · filed 2026-03-09 | $19.09M derived: sum of 4 quarters · filed 2026-03-09 | |||
| 2023-12-31 | $4.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $9.15M derived: sum of 2 quarters · filed 2026-03-09 | $13.54M derived: sum of 3 quarters · filed 2026-03-09 | $18.37M 10-K · filed 2026-03-09 | |||
| 2023-09-30 | $4.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $9.18M derived: sum of 2 quarters · filed 2024-11-05 | $14.01M 10-Q · filed 2024-11-05 | $18.75M derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2023-06-30 | $4.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $9.22M 10-Q · filed 2024-08-06 | $13.96M derived: sum of 3 quarters · filed 2025-03-20 | $19.09M derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2023-03-31 | $4.83M 10-Q · filed 2024-05-09 | $9.57M derived: sum of 2 quarters · filed 2025-03-20 | $14.70M derived: sum of 3 quarters · filed 2025-03-20 | $20.00M derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2022-12-31 | $4.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $9.86M derived: sum of 2 quarters · filed 2025-03-20 | $15.16M derived: sum of 3 quarters · filed 2025-03-20 | $20.44M 10-K · filed 2025-03-20 | |||
| 2022-09-30 | $5.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $10.42M derived: sum of 2 quarters · filed 2023-11-06 | $15.70M 10-Q · filed 2023-11-06 | $21.11M derived: sum of 4 quarters · filed 2024-03-07 | |||
| 2022-06-30 | $5.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $10.57M 10-Q · filed 2023-08-09 | $15.99M derived: sum of 3 quarters · filed 2024-03-07 | $22.34M derived: sum of 4 quarters · filed 2024-03-07 | |||
| 2022-03-31 | $5.27M 10-Q · filed 2023-05-09 | $10.69M derived: sum of 2 quarters · filed 2024-03-07 | $17.04M derived: sum of 3 quarters · filed 2024-03-07 | $23.11M derived: sum of 4 quarters · filed 2024-03-07 | |||
| 2021-12-31 | $5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $11.77M derived: sum of 2 quarters · filed 2024-03-07 | $17.84M derived: sum of 3 quarters · filed 2024-03-07 | $23.13M 10-K · filed 2024-03-07 | |||
| 2021-09-30 | $6.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $12.43M derived: sum of 2 quarters · filed 2022-11-03 | $17.71M 10-Q · filed 2022-11-03 | $22.97M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2021-06-30 | $6.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $11.36M 10-Q · filed 2022-08-08 | $16.61M derived: sum of 3 quarters · filed 2023-03-15 | $22.45M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2021-03-31 | $5.29M 10-Q · filed 2022-05-03 | $10.54M derived: sum of 2 quarters · filed 2023-03-15 | $16.38M derived: sum of 3 quarters · filed 2023-03-15 | $21.47M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2020-12-31 | $5.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $11.09M derived: sum of 2 quarters · filed 2023-03-15 | $16.18M derived: sum of 3 quarters · filed 2023-03-15 | $20.68M 10-K · filed 2023-03-15 | |||
| 2020-09-30 | $5.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $10.93M derived: sum of 2 quarters · filed 2021-11-02 | $15.42M 10-Q · filed 2021-11-02 | $20.91M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-06-30 | $5.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $9.59M 10-Q · filed 2021-07-29 | $15.08M derived: sum of 3 quarters · filed 2022-02-24 | $20.48M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-03-31 | $4.49M 10-Q · filed 2021-04-29 | $9.98M derived: sum of 2 quarters · filed 2022-02-24 | $15.38M derived: sum of 3 quarters · filed 2022-02-24 | $20.26M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2019-12-31 | $5.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $10.89M derived: sum of 2 quarters · filed 2022-02-24 | $15.77M derived: sum of 3 quarters · filed 2022-02-24 | $19.57M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $5.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $10.28M derived: sum of 2 quarters · filed 2020-11-04 | $14.08M 10-Q · filed 2020-11-04 | $18.43M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | $4.88M 10-Q · filed 2019-07-31 | $8.68M 10-Q · filed 2020-07-31 | $13.04M derived: sum of 3 quarters · filed 2021-02-25 | $17.61M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | $3.80M 10-Q · filed 2020-05-05 | $8.15M derived: sum of 2 quarters · filed 2021-02-25 | $12.72M derived: sum of 3 quarters · filed 2021-02-25 | $16.89M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $8.93M derived: sum of 2 quarters · filed 2021-02-25 | $13.09M derived: sum of 3 quarters · filed 2021-02-25 | $16.52M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $4.57M 10-Q · filed 2018-11-07 | $8.74M derived: sum of 2 quarters · filed 2019-07-31 | $12.17M 10-Q · filed 2019-11-06 | $15.85M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-06-30 | $4.16M 10-Q · filed 2019-07-31 | $7.59M 10-Q · filed 2019-07-31 | $11.28M derived: sum of 3 quarters · filed 2020-02-25 | $15.28M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-03-31 | $3.43M 10-Q · filed 2019-05-01 | $7.11M derived: sum of 2 quarters · filed 2020-02-25 | $11.11M derived: sum of 3 quarters · filed 2020-02-25 | $14.71M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2017-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $7.68M derived: sum of 2 quarters · filed 2020-02-25 | $11.28M derived: sum of 3 quarters · filed 2020-02-25 | $14.74M 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $4.00M 10-Q · filed 2018-11-07 | $7.60M derived: sum of 2 quarters · filed 2018-11-07 | $11.06M 10-Q · filed 2018-11-07 | $14.10M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-06-30 | $3.60M 10-Q · filed 2018-08-07 | $7.06M 10-Q · filed 2018-08-07 | $10.10M derived: sum of 3 quarters · filed 2019-02-26 | $13.11M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-03-31 | $3.46M 10-Q · filed 2018-05-07 | $6.50M derived: sum of 2 quarters · filed 2019-02-26 | $9.50M derived: sum of 3 quarters · filed 2019-02-26 | $12.63M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2016-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $6.04M derived: sum of 2 quarters · filed 2019-02-26 | $9.16M derived: sum of 3 quarters · filed 2019-02-26 | $12.16M 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $3.00M 10-Q · filed 2017-11-08 | $6.13M derived: sum of 2 quarters · filed 2017-11-08 | $9.13M 10-Q · filed 2017-11-08 | $11.34M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | $3.12M 10-Q · filed 2017-08-02 | $6.12M 10-Q · filed 2017-08-02 | $8.34M derived: sum of 3 quarters · filed 2018-02-27 | $10.44M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | $3.00M 10-Q · filed 2017-05-03 | $5.22M derived: sum of 2 quarters · filed 2018-02-27 | $7.32M derived: sum of 3 quarters · filed 2018-02-27 | $9.22M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | $2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $4.31M derived: sum of 2 quarters · filed 2018-02-27 | $6.22M derived: sum of 3 quarters · filed 2018-02-27 | $7.85M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $2.10M 10-Q · filed 2016-11-02 | $4.00M derived: sum of 2 quarters · filed 2016-11-02 | $5.63M 10-Q · filed 2016-11-02 | $6.63M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | $1.90M 10-Q · filed 2016-08-03 | $3.53M 10-Q · filed 2016-08-03 | $4.53M derived: sum of 3 quarters · filed 2017-02-28 | $5.38M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | $1.63M 10-Q · filed 2016-05-04 | $2.63M derived: sum of 2 quarters · filed 2017-02-28 | $3.48M derived: sum of 3 quarters · filed 2017-02-28 | $4.26M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | $995.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $1.85M derived: sum of 2 quarters · filed 2017-02-28 | $2.63M derived: sum of 3 quarters · filed 2017-02-28 | $3.24M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | $856.00K 10-Q · filed 2015-11-04 | $1.64M derived: sum of 2 quarters · filed 2015-11-04 | $2.25M 10-Q · filed 2015-11-04 | $2.72M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $781.00K 10-Q · filed 2015-08-05 | $1.39M 10-Q · filed 2015-08-05 | $1.86M derived: sum of 3 quarters · filed 2016-02-29 | $2.00M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $612.00K 10-Q · filed 2015-05-06 | $611.60K 10-Q · filed 2014-05-06 | $1.08M derived: sum of 2 quarters · filed 2016-02-29 | $1.22M derived: sum of 3 quarters · filed 2016-02-29 | $1.33M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | $468.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $605.00K derived: sum of 2 quarters · filed 2016-02-29 | $717.00K derived: sum of 3 quarters · filed 2016-02-29 | $862.00K 10-K · filed 2016-02-29 | $862.16K 10-K · filed 2014-03-20 | ||
| 2013-09-30 | $137.00K 10-Q · filed 2014-11-12 | $249.00K derived: sum of 2 quarters · filed 2014-11-12 | $394.00K 10-Q · filed 2014-11-12 | $393.56K 10-Q · filed 2013-11-12 | $603.08K derived: sum of 4 quarters · filed 2015-03-03 | ||
| 2013-06-30 | $112.00K 10-Q · filed 2014-08-05 | $257.00K 10-Q · filed 2014-08-05 | $466.08K derived: sum of 3 quarters · filed 2015-03-03 | ||||
| 2013-03-31 | $144.87K 10-Q · filed 2014-05-06 | $354.08K derived: sum of 2 quarters · filed 2015-03-03 | |||||
| 2012-12-31 | $209.20K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $838.00K 10-K · filed 2015-03-03 | $838.39K 10-K · filed 2014-03-20 | ||||
| 2012-09-30 | $628.80K 10-Q · filed 2013-11-12 | ||||||
| 2011-12-31 | $2.35M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |